07:00 , Aug 20, 2012 |  BC Week In Review  |  Company News

Cancer Therapeutics CRC, Cancer Research U.K. deal

The research center's commercial arm Cancer Research Technology (CRT) Ltd. exercised an option to sublicense exclusive, worldwide rights to develop and commercialize Cancer Therapeutics' CTx-0294945 and CTx-0294886 . CTx-0294945 is a highly-selective small molecule inhibitor...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Cancer Therapeutics CRC preclinical data

In a mouse model of TNBC, 80 mg/kg oral CTX-0294945 plus Avastin bevacizumab inhibited tumor growth by 88% at day 28 compared to 75% for Avastin alone. At day 28, tumors in mice receiving vehicle...